Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganaxolone in CDKL5 Deficiency Disorder (Marigold)
NCT03572933Phase 3Completed
- Sponsor
- Marinus Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Jul 2020
- Modality
- Allosteric Modulators
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in CDKL5 deficiency disorder (CDD) comparing Ganaxolone with Placebo (2 arms). Primary endpoint: Percent Reduction in 28-day Seizure Frequency for Major Motor Seizure Types at 17 weeks. Started Jun 2018; status: completed.
02
Drugs
ganaxolone
03
Conditions
CDKL5 deficiency disorder (CDD)
Beyond the preview
Go deeper on NCT03572933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03572933.